Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies

All companies

257 clinical-stage companies. Search or filter to narrow the list.

Ticker Company Therapeutic areas Lead stage Mkt cap Programs
FDMT 4D Molecular Therapeutics OphthalmologyRespiratory Rare Phase 3 $677M 5
AARD Aardvark Therapeutics DermatologyMetabolic+1 Rare Phase 3 $25.6M 3
ABVX Abivax Immunology Phase 3 $7.50B 2
ABSI Absci DermatologyGI/Hepatology+1 Phase 1 $1.75B 6
ACIU AC Immune Neurology Rare Phase 3 $222M 11
ACHV Achieve Life Sciences — NDA Submitted $692M 2
ACRS Aclaris Therapeutics DermatologyGI/Hepatology+1 Rare Phase 2 $619M 8
ACRV Acrivon Therapeutics GI/HepatologyOncology Rare Phase 2 $69.0M 9
ACTU Actuate Therapeutics Oncology Phase 2 $7.9M 4
ABOS Acumen Pharmaceuticals Neurology Phase 2 $16.2M 4
ADAG Adagene Oncology Phase 2 $134M 10
ADCT ADC Therapeutics Oncology Approved $202M 5
ACET Adicet Bio ImmunologyNeurology+2 Rare Phase 1 $28.6M 8
ADMA Adma Biologics ImmunologyInfectious Disease Rare Approved $2.82B 4
AGIO Agios Pharmaceuticals HematologyMetabolic Rare Approved $1.76B 7
AGMB Agomab Therapeutics ImmunologyRespiratory Rare Phase 2 $376M 4
AKBA Akebia Therapeutics HematologyOphthalmology+2 Rare Approved $111M 10
AKTS Aktis Oncology Oncology Phase 1 $880M 10
ALDX Aldeyra Therapeutics DermatologyOncology+1 NDA Submitted $38.3M 5
ALLO Allogene Therapeutics ImmunologyOncology Rare Phase 2 $360M 10
DRTS Alpha Tau Medical Oncology Phase 2 $1.27B 6
ATHE Alterity Therapeutics Neurology Rare Phase 2 $46.4M 2
ALT Altimmune GI/HepatologyMetabolic+1 Phase 3 $405M 3
AMLX Amylyx Pharmaceuticals MetabolicNeurology Rare Phase 3 $3.79B 5
ANTX AN2 Therapeutics HematologyInfectious Disease+1 Rare Phase 2 $151M 6
ANAB AnaptysBio DermatologyGI/Hepatology+2 Rare Approved $1.39B 9
ANIX Anixa Biosciences Oncology Phase 1 $111M 3
ANNX Annexon HematologyNeurology+2 Rare Phase 3 $796M 6
APGE Apogee Therapeutics DermatologyGI/Hepatology+1 Rare Phase 2 — 9
APVO Aptevo Therapeutics Oncology Phase 1 $2.2M 8
RCUS Arcus Biosciences DermatologyImmunology+1 Phase 3 $2.63B 8
ARDX Ardelyx GI/HepatologyRenal Approved $724M 4
ARTV Artiva Biotherapeutics Oncology — $203M 6
ARVN Arvinas NeurologyOncology Rare Approved $420M 10
ATAI Atai Beckley Neurology Phase 2 $2.73B 5
AUTL Autolus Therapeutics HematologyImmunology+3 Rare Approved $341M 12
AXSM Axsome Therapeutics Neurology Rare Approved $6.96B 15
BEAM Beam Therapeutics HematologyMetabolic+1 Rare Phase 2 $2.73B 6
BLTE Belite Bio MetabolicOphthalmology Rare NDA Submitted $6.21B 6
BCAX Bicara Therapeutics Oncology Phase 2 $572M 4
BCYC Bicycle Therapeutics Oncology Phase 2 $253M 4
BIOA BioAge Labs CardiovascularOphthalmology Phase 2 $245M 2
BCRX Biocryst Pharmaceuticals DermatologyImmunology+1 Rare Approved $1.98B 4
BMEA Biomea Fusion MetabolicOncology Phase 2 $41.1M 4
BDTX Black Diamond Therapeutics Oncology Phase 2 $99.7M 4
BCTX BriaCell Therapeutics Oncology Phase 3 $34.5M 8
BBOT BridgeBio Oncology Therapeutics Oncology Phase 1 $164M 6
CCCC C4 Therapeutics Oncology Phase 2 $407M 2
CABA Cabaletta Bio DermatologyImmunology+2 Rare Phase 2 $280M 8
CADL Candel Therapeutics Oncology Phase 3 $670M 4
CAPR Capricor Therapeutics Infectious DiseaseNeurology Rare NDA Submitted $523M 2
CRDL Cardiol Therapeutics Cardiovascular Rare Phase 3 $121M 4
CRBU Caribou Biosciences — — $48.5M 0
RNAC Cartesian Therapeutics ImmunologyNeurology+1 Rare Phase 3 $230M 4
CLDX Celldex Therapeutics DermatologyImmunology+1 Phase 3 $2.35B 9
CLRB Cellectar Biosciences Oncology Phase 2 $11.8M 6
IPSC Century Therapeutics ImmunologyMetabolic+1 Rare Phase 1 $304M 9
CRVO CervoMed Neurology Rare Phase 2 $21.5M 4
CGON CG Oncology Oncology NDA Submitted $6.79B 1
CMMB Chemomab Therapeutics GI/HepatologyImmunology+1 Rare Phase 2 $10.6M 4
CING Cingulate Neurology NDA Submitted $61.9M 1
CLNN Clene Neurology Rare NDA Submitted $56.9M 5
CLYM Climb Bio HematologyImmunology+1 Rare Phase 2 $604M 8
COGT Cogent Biosciences HematologyOncology Rare NDA Submitted $5.51B 7
CGTX Cognition Therapeutics Neurology Phase 2 $65.3M 2
CHRS Coherus Oncology Oncology Approved $119M 4
CMPS COMPASS Pathways Neurology NDA Submitted $1.22B 3
CMPX Compass Therapeutics Oncology Phase 2 $137M 15
CGEN Compugen Oncology Phase 3 $186M 7
CNTB Connect Biopharma Respiratory Phase 2 $45.9M 4
CTNM Contineum Therapeutics NeurologyRespiratory Rare Phase 2 $374M 4
CRVS Corvus Pharmaceuticals DermatologyOncology+1 Rare Phase 3 $889M 7
COYA Coya Therapeutics Neurology Rare Phase 2 $70.1M 6
CBIO Crescent Biopharma Oncology Phase 2 $503M 10
CRNX Crinetics Pharmaceuticals MetabolicOncology Rare Approved — 6
CUE Cue Biopharma ImmunologyOncology Phase 2 $136M 6
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare NDA Submitted $728M 10
CYDY CytoDyn NeurologyOncology Phase 2 $338M 3
CTMX CytomX Therapeutics Oncology Phase 1 $477M 7
DBVT DBV Technologies Immunology NDA Submitted $3.29B 2
DFTX Definium Therapeutics Neurology Phase 3 $4.47B 4
IRON Disc Medicine GI/HepatologyHematology+2 Rare Phase 3 $3.59B 9
DYN Dyne Therapeutics MetabolicNeurology Rare NDA Submitted $3.39B 10
EWTX Edgewise Therapeutics Cardiovascular Phase 2 $4.93B 3
EIKN Eikon Therapeutics Oncology Phase 2 $320M 13
ELDN Eledon Pharmaceuticals ImmunologyMetabolic+1 Rare Phase 2 $212M 3
ELTX Elicio Therapeutics Oncology Phase 2 $42.7M 6
ELOX Eloxx Pharmaceuticals DermatologyRenal Rare Phase 2 $50.2M 4
ENTA Enanta Pharmaceuticals DermatologyImmunology+1 Approved $320M 7
ELVN Enliven Therapeutics Oncology Phase 1 $3.64B 1
ENTX Entera Bio GI/HepatologyMetabolic Rare Phase 2 $547M 4
ERAS Erasca Oncology Phase 1 $5.04B 5
ETON Eton Pharmaceuticals GI/HepatologyInfectious Disease+3 Rare Approved $1.63B 17
EVMN Evommune DermatologyImmunology+1 Phase 2 $241M 6
EXEL Exelixis CardiovascularOncology Approved $17.0B 23
EYPT EyePoint Ophthalmology Phase 3 $31.0M 2
FATE Fate Therapeutics ImmunologyOncology+1 Rare Phase 2 $224M 10
FHTX Foghorn Therapeutics Oncology Preclinical $111M 4
FBRX Forte Biosciences DermatologyGI/Hepatology Phase 2 — 3
FBIO Fortress Biotech DermatologyHematology+3 Rare Approved $61.7M 12
GUTS Fractyl Health Metabolic Phase 3 — 1
GANX Gain Therapeutics MetabolicNeurology Rare Phase 1 $45.0M 5
GNLX Genelux Oncology Phase 3 $88.7M 3
GERN Geron Oncology Approved $638M 3
GHRS GH Research NeurologyWomen's Health Phase 2 $1.28B 4
GOSS Gossamer Bio Cardiovascular Rare NDA Submitted — 4
GRCE Grace Therapeutics Neurology NDA Submitted $38.9M 1
GLSI Greenwich LifeSciences Oncology Phase 3 $223M 1
HRMY Harmony Biosciences MetabolicNeurology Rare Approved $1.94B 17
HROW Harrow Ophthalmology Rare Approved $1.01B 15
HELP Helus Pharma Neurology Phase 3 $655M 3
IDYA IDEAYA Biosciences Oncology NDA Submitted $3.02B 14
IMTX Immatics Oncology Phase 3 $968M 8
IMMX Immix Biopharma Hematology Rare Phase 1 $577M 1
IMRX Immuneering Oncology Phase 3 $238M 5
IMUX Immunic GI/HepatologyNeurology Phase 3 $106M 4
IBRX ImmunityBio Infectious DiseaseOncology Approved $9.15B 16
IMCR Immunocore DermatologyInfectious Disease+2 Approved $1.60B 15
IMNM Immunome Oncology Rare NDA Submitted $2.13B 9
IMVT Immunovant ImmunologyNeurology Rare Phase 3 $6.31B 5
INAB IN8bio ImmunologyOncology Phase 1 $10.0M 4
IXHL Incannex Healthcare NeurologyRespiratory Phase 2 $28.1M 2
INBX Inhibrx Biosciences Oncology NDA Submitted $1.24B 6
INMB Inmune Bio Dermatology Rare Phase 3 $35.0M 1
INSM Insmed CardiovascularImmunology+3 Rare Approved $25.1B 15
NTLA Intellia Therapeutics CardiovascularImmunology Rare NDA Submitted $1.59B 3
IVVD Invivyd Infectious Disease Approved $166M 5
IONS Ionis Pharmaceuticals CardiovascularHematology+5 Rare Approved $6.55B 29
JBIO Jade Biosciences ImmunologyRenal Rare Phase 2 $958M 4
JANX Janux Therapeutics Oncology Phase 1 $1.08B 4
KAPA Kairos Pharma Oncology Phase 2 — 13
KZIA Kazia Therapeutics NeurologyOncology Rare Phase 2 $82.0M 13
KROS Keros Therapeutics NeurologyOncology Rare Phase 3 $184M 5
KPRX Kiora Pharmaceuticals Ophthalmology Rare Phase 3 $6.4M 4
KOD Kodiak Sciences Ophthalmology Phase 3 $6.24B 8
KURA Kura Oncology MetabolicOncology Approved $647M 12
KYMR Kymera Therapeutics DermatologyImmunology+1 Rare Phase 2 $11.2B 5
KYTX Kyverna Therapeutics ImmunologyNeurology+1 Rare NDA Submitted $302M 7
LRMR Larimar Therapeutics Neurology Rare NDA Submitted $248M 1
LBRX LB Pharmaceuticals Neurology Phase 3 $1.36B 3
LEGN Legend Biotech Oncology Rare Approved $4.55B 17
LENZ LENZ Therapeutics Ophthalmology Approved $110M 1
LXEO Lexeo Therapeutics CardiovascularNeurology Rare Phase 2 $237M 12
LCTX Lineage Cell Therapeutics MetabolicNeurology+1 Rare Phase 2 $258M 12
LQDA Liquidia CardiovascularImmunology+1 Rare Approved $3.97B 9
LGVN Longeveron CardiovascularMetabolic+1 Rare Phase 2 $5.8M 4
MAIA MAIA Biotechnology Oncology Phase 3 $64.5M 7
MPLT MapLight Therapeutics Neurology Phase 2 $385M 6
MRKR Marker Therapeutics Oncology Phase 1 $14.8M 4
MAZE Maze Therapeutics MetabolicRenal Rare Phase 2 $1.90B 4
MDNAF Medicenna Therapeutics Oncology Phase 2 $29.5M 10
MGTX MeiraGTx ImmunologyMetabolic+2 Rare Phase 3 $864M 16
MESO Mesoblast CardiovascularGI/Hepatology+2 Rare Approved $1.85B 5
MIST Milestone Pharmaceuticals Cardiovascular Approved $95.0M 2
MLYS Mineralys Therapeutics CardiovascularRenal+1 NDA Submitted $1.36B 3
INKT MiNK Therapeutics ImmunologyOncology+1 Rare Phase 2 $52.8M 8
MBRX Moleculin Biotech Oncology Phase 2 — 8
GLUE Monte Rosa Therapeutics CardiovascularDermatology+3 Rare Phase 2 $903M 7
MLTX MoonLake Immunotherapeutics DermatologyImmunology Rare NDA Submitted $981M 4
NKTR Nektar Therapeutics DermatologyImmunology+2 Phase 3 $1.27B 11
NGEN NervGen Pharma Neurology Phase 3 $143M 3
NGNE Neurogene Neurology Rare Phase 3 $506M 1
NRSN NeuroSense Therapeutics Neurology Rare Phase 2 $3.2M 3
NAMS NewAmsterdam Pharma CardiovascularMetabolic+1 NDA Submitted $2.27B 6
NKTX Nkarta ImmunologyNeurology+1 Rare Phase 1 $124M 8
NBP NovaBridge Biosciences OncologyOphthalmology Phase 2 $106M 7
NRXP NRX Pharmaceuticals Neurology Rare Approved $103M 7
NRIX Nurix Therapeutics ImmunologyNeurology+1 Phase 3 $1.67B 13
NVCT Nuvectis Pharma HematologyOncology+1 Rare Phase 3 $719M 9
OCGN Ocugen Infectious DiseaseOphthalmology Rare Phase 3 $314M 12
OCS Oculis Holding NeurologyOphthalmology Rare Phase 3 $417M 5
OLMA Olema Pharmaceuticals Oncology Phase 3 $641M 3
OMER Omeros HematologyNeurology+2 Rare Approved $1.22B 6
ONCY Oncolytics Biotech Oncology Phase 2 $56.1M 3
OKUR OnKure Therapeutics Oncology Preclinical $116M 2
IRD Opus Genetics Ophthalmology Rare Approved $348M 12
ORIC Oric Pharmaceuticals Oncology Phase 3 $914M 5
ORKA Oruka Therapeutics DermatologyImmunology Rare Phase 2 $6.81B 7
OTLK Outlook Therapeutics Ophthalmology Approved $106M 3
OVID Ovid Therapeutics Neurology Rare Phase 2 $557M 4
PTN Palatin Technologies ImmunologyMetabolic+1 Rare Phase 3 $11.2M 8
PALI Palisade Bio Immunology Phase 2 $197M 3
KTTA Pasithea Therapeutics NeurologyOncology Rare Phase 1 $19.3M 4
PEPG PepGen Neurology Rare Phase 2 $171M 1
CATX Perspective Therapeutics Oncology Phase 1 $95.9M 4
PHIO Phio Pharmaceuticals Oncology Phase 1 $9.6M 4
PMVP PMV Pharmaceuticals Oncology Phase 2 $67.4M 7
PYPD PolyPid Infectious DiseaseOncology NDA Submitted $125M 3
DTIL Precision Biosciences Infectious DiseaseMetabolic+1 Rare Phase 1 $296M 5
PRLD Prelude Therapeutics HematologyOncology Rare Phase 1 $287M 3
PCSA Processa Pharmaceuticals GI/HepatologyImmunology+2 Rare Phase 2 $5.4M 7
PMN ProMIS Neurosciences Neurology Rare Phase 1 $37.3M 6
PRQR ProQR Therapeutics MetabolicNeurology Rare Phase 1 $191M 7
PTGX Protagonist Therapeutics DermatologyHematology+2 Rare Approved $8.62B 12
TARA Protara Therapeutics DermatologyMetabolic+1 Rare Phase 3 $142M 3
QTTB Q32 Bio Dermatology Phase 2 $277M 3
QNRX Quoin Pharmaceuticals DermatologyImmunology Rare Phase 2 $257M 4
RAPP Rapport Therapeutics Neurology Phase 3 $1.45B 10
RXRX Recursion Pharmaceuticals Oncology Phase 2 $2.19B 6
RNTX Rein Therapeutics Respiratory Rare Phase 2 $53.0M 1
RLAY Relay Therapeutics DermatologyOncology Rare Approved $4.11B 4
RLMD Relmada Therapeutics MetabolicNeurology+1 Rare Phase 2 $416M 4
REPL Replimune Group Oncology Approved $2.05B 5
RVPH Reviva Pharmaceuticals CardiovascularDermatology+2 Rare Phase 3 $4.8M 10
RVMD Revolution Medicines Oncology Approved $41.6B 11
RYTM Rhythm Pharmaceuticals Metabolic Rare Approved $7.78B 14
RCKT Rocket Pharmaceuticals CardiovascularImmunology Rare Approved $262M 4
SABS SAB Biotherapeutics Metabolic Phase 2 $273M 1
SGMT Sagimet Biosciences DermatologyMetabolic Phase 3 $698M 3
SANA Sana Biotechnology MetabolicOncology Phase 1 $710M 4
SRPT Sarepta Therapeutics NeurologyRespiratory Rare Approved $1.91B 11
SCYX Scynexis Infectious DiseaseRenal Rare Approved $34.8M 5
SLS SELLAS Life Sciences Group Oncology Phase 3 $1.70B 9
SEPN Septerna ImmunologyMetabolic+1 Rare Phase 1 $2.28B 5
SION Sionna Therapeutics Respiratory Rare Phase 2 $148M 5
SLDB Solid Biosciences CardiovascularNeurology Rare Phase 3 $736M 6
SPRB Spruce Biosciences Metabolic Rare Preclinical $134M 2
SYRE Spyre Therapeutics DermatologyImmunology Rare Phase 2 $9.86B 10
STOK Stoke Therapeutics Neurology Rare Phase 3 $1.74B 2
GPCR Structure Therapeutics MetabolicRespiratory Rare Phase 3 $4.35B 5
SMMT Summit Therapeutics Oncology NDA Submitted $13.1B 6
STRO Sutro Biopharma Oncology Phase 1 $160M 4
SNDX Syndax Pharmaceuticals ImmunologyOncology Rare Approved $852M 7
TNGX Tango Therapeutics Oncology Phase 1 $3.63B 4
TSHA Taysha Gene Therapies Neurology Rare Phase 3 $1.41B 4
TECX Tectonic Therapeutic Cardiovascular Rare Phase 2 $412M 4
TLX Telix Pharmaceuticals Oncology Approved $3.27B 25
TENX Tenax Therapeutics Cardiovascular Rare Phase 3 $77.0M 2
TGTX Tg Therapeutics Neurology Rare Approved $9.16B 6
TLSA Tiziana Life Sciences ImmunologyNeurology Rare Phase 2 $87.8M 5
TVTX Travere Therapeutics MetabolicRenal Rare Approved $4.76B 7
HURA TuHURA Biosciences Oncology Phase 3 $104M 4
TTRX Turn Therapeutics DermatologyInfectious Disease Rare Phase 2 $282M 4
TYRA Tyra Biosciences MetabolicOncology Rare Phase 2 $1.26B 5
RARE Ultragenyx Pharmaceutical CardiovascularMetabolic+1 Rare Approved $1.57B 10
UNCY Unicycive Therapeutics Renal NDA Submitted $98.9M 2
QURE uniQure HematologyMetabolic+1 Rare Approved $1.52B 4
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare Approved $231M 27
PCVX Vaxcyte Infectious Disease Phase 3 $10.1B 7
VERA Vera Therapeutics Infectious DiseaseRenal Rare Approved $2.15B 6
VSTM Verastem Oncology Approved $1.06B 5
VRCA Verrica Pharmaceuticals DermatologyOncology Approved $54.8M 3
VKTX Viking Therapeutics MetabolicNeurology Rare Phase 3 $3.42B 9
VIR Vir Biotechnology Infectious DiseaseOncology Rare Phase 3 $2.09B 12
VRDN Viridian Therapeutics ImmunologyOphthalmology Approved $3.24B 7
VOR Vor Biopharma ImmunologyNeurology Rare Phase 3 $1.22B 2
VYGR Voyager Therapeutics MetabolicNeurology Rare Phase 1 $116M 9
VTVT vTv Therapeutics HematologyMetabolic+1 Rare Phase 3 $84.4M 9
WVE Wave Life Sciences MetabolicNeurology+1 Rare Phase 2 $665M 5
XFOR X4 Pharmaceuticals — Approved $325M 2
XNCR Xencor ImmunologyNeurology+1 Rare Approved $2.68B 28
XENE Xenon Pharmaceuticals Neurology Rare NDA Submitted $3.79B 9
XERS Xeris Biopharma MetabolicNeurology Rare Approved $2.78B 4
ZBIO Zenas BioPharma DermatologyImmunology+2 Rare NDA Submitted $1.92B 11
ZNTL Zentalis Pharmaceuticals Oncology Phase 3 $123M 1
ZURA Zura Bio DermatologyImmunology Rare Phase 2 $394M 5
ZYME Zymeworks OncologyRespiratory Approved $2.10B 11